Back to Search
Start Over
Botulinum toxin type A is a potential therapeutic drug for chronic orofacial pain
- Source :
- Journal of Oral Biosciences; September 2024, Vol. 66 Issue: 3 p496-503, 8p
- Publication Year :
- 2024
-
Abstract
- Botulinum toxin type A (BTX-A), produced by the gram-positive anaerobic bacterium Clostridium botulinum, acts by cleaving synaptosome-associated protein-25 (SNAP-25), an essential component of the presynaptic neuronal membrane that is necessary for fusion with the membrane proteins of neurotransmitter-containing vesicles. Recent studies have highlighted the efficacy of BTX-A in treating chronic pain conditions, including lower back pain, chronic neck pain, neuropathic pain, and trigeminal neuralgia, particularly when patients are unresponsive to traditional painkillers. This review focuses on the analgesic effects of BTX-A in various chronic pain conditions, with a particular emphasis on the orofacial region.
Details
- Language :
- English
- ISSN :
- 13490079
- Volume :
- 66
- Issue :
- 3
- Database :
- Supplemental Index
- Journal :
- Journal of Oral Biosciences
- Publication Type :
- Periodical
- Accession number :
- ejs66687891
- Full Text :
- https://doi.org/10.1016/j.job.2024.06.004